Which Indian traditional medicines are being eyed for COVID-19?
This review prioritizes AYUSH formulations and Indian plants with antiviral, immunomodulatory, and anti-inflammatory records for COVID-19 testing amid India’s then-<1.5% case fatality narrative.
Source
Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research
What they did
Reviewed AYUSH-recommended formulations/ingredients, commonly used Indian medicinal plants, and plants with antiviral/immunomodulatory/anti-allergic–anti-inflammatory reports, categorizing them for research prioritization and summarizing ongoing AYUSH clinical-trial activity.
What they found
Authors argue routine immunomodulator plant/AYUSH use may relate to India’s relatively lower reported fatality, highlight immunity-enhancing/anti-inflammatory/antiviral herbal evidence, note >50% of related trials linked to Ministry of AYUSH stakeholders, and urge priority preclinical/clinical testing of promising leads.
The limits
What it doesn't show
Not an RCT proving any named herb cures COVID-19; causal claims about national fatality rates are speculative.
Key terms
- AYUSH
- India’s traditional medicine systems ministry/framework (Ayurveda, Yoga, etc.).
- Immunomodulator
- Agent that alters immune responses.
- ARDS
- Acute respiratory distress syndrome in severe COVID-19.
- Adjuvant
- Add-on therapy alongside standard care.
- Prophylaxis
- Preventive use before or early in exposure/disease.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
This article is primarily a:
Common questions
Study type?
Narrative review of plants/formulations and trials.
Cited India CFR context?
Below 1.50% in the paper’s timeframe.
Emphasis activities?
Antiviral, immunomodulatory, anti-allergic/anti-inflammatory.
Trial funding note?
>50% linked to government/AYUSH stakeholders.
More on pharmacology